文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

CDK9抑制剂FIT039治疗寻常疣的疗效:一项随机对照试验的研究方案

The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-08-09

该研究为多机构、单盲、安慰剂对照的随机I/II期临床试验,计划纳入44例四肢寻常疣成人患者,随机分为FIT039透皮贴剂组或对照组,干预14天,随访2个月,主要疗效终点为疣消退,安全性终点为不良事件和药物不良反应发生率。

要点

  • FIT039是CDK9抑制剂,体外可抑制HPV等DNA病毒增殖。
  • 研究设计为多机构、单盲、安慰剂对照随机I/II期试验,样本44例。
  • 主要疗效终点为疣消退,安全性终点为不良事件和药物不良反应。

核心结论

  • 该研究首次评估FIT039的疗效,将有助于开发可治愈免疫功能低下患者难治性寻常疣的抗病毒药物。

研究设计与样本

  • 多机构、单盲、安慰剂对照的随机I/II期临床试验,计划纳入44例四肢寻常疣且无严重合并症的成人患者。
  • 干预组使用释放FIT039的透皮贴剂,对照组使用安慰剂,干预持续14天。
  • 在基线和干预后评估结局,并在2个月随访时进一步评估。

主要发现

  • 主要疗效终点为疣消退。
  • 安全性终点为不良事件和药物不良反应的发生率。
  • 次要终点为疣尺寸变化、疣横截面积变化和疣区域内血栓数量变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human papilloma viruses (HPVs) infect squamous epithelial cells and form verrucous lesions, or warts. Besides the psychosocial problems caused by the disfiguring warts, a subset of HPVs can be the primary etiologic agent for malignancies such as cervical cancer. However, there is no curative antiviral therapy for HPV infection. We recently found that the viral RNA transcription of DNA viruses requires cyclin dependent kinase 9 (CDK9) in the host cells, and that FIT039, a specific inhibitor of CDK9, suppressed the proliferation of DNA viruses such as herpes simplex virus 1 (HSV-1), HSV-2, human adenovirus, human cytomegalovirus, hepatitis virus B, and HPVs. Here, we describe a protocol to evaluate the safety and antiviral effect of FIT039 on common warts in human skin. METHODS AND DESIGN: A multi-institutional, single-blind, placebo-controlled randomized phase I/II clinical trial was designed to evaluate the safety and efficacy of FIT039 on common warts on the extremities. A total of 44 adults with a primary diagnosis of verruca vulgaris on the extremities without serious comorbidities will be randomized into either the intervention group with an FIT039-releasing transdermal patch or a control group for a duration of 14 days. Outcomes will be assessed at baseline and postintervention. Participants will be further assessed at 2 months follow-up. The primary endpoint for efficacy is the resolution of the warts. The safety endpoint is the incidence of adverse events and adverse drug reactions. The secondary endpoints are changes in the dimensions of the wart, the cross-sectional area of the wart, and the number of clots within the area of the wart. DISCUSSION: This study is the first to assess the efficacy of FIT039 and will contribute to the development of antiviral agents that can cure refractory common warts in immunocompromised patients. TRIAL REGISTRATION: UMIN Clinical Trials, UMIN000029695 . Registered on 1 November 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nomura T, Sumi E, Egawa G, et al. The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial. Trials. 2019. PMID: 31399147. doi:10.1186/s13063-019-3570-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。